Skip to content
All compound profiles

EVIDENCE PROFILE / PUBLISHED

Cagrilintide

Cagrilintide is a long-acting amylin analogue under clinical development. A multinational phase 2 dose-finding trial randomized 706 participants to cagrilintide doses, 99 to liraglutide, and 101 to placebo and reported weight-loss and tolerability outcomes.

Aliases reviewed
AM833, Cagri
Sources checked
2026-09-15
Editorial status
published

Evidence at a glance

Human
LimitedOne large randomized phase 2 trial.
Animal/cell
Not rated
Approved medicine
Not rated

Summarises how much research the profile's sources report, and of what kind. It is not a verdict on the compound or on any catalogue material.

PREPPY BOY ASKS

“A familiar name can hide a different molecule, fragment, formulation, or evidence story.”

The catalogue name is a starting point, not proof of formulation or identity. Research examines satiety signaling, body weight, metabolic endpoints, and combination regimens.

Identity

Cagrilintide is a long-acting amylin analogue under clinical development.

Biological mechanism or research interest

Research examines satiety signaling, body weight, metabolic endpoints, and combination regimens.

Verified approved human uses

No approved standalone cagrilintide medicine was verified in the reviewed sources.

Investigational human evidence

A multinational phase 2 dose-finding trial randomized 706 participants to cagrilintide doses, 99 to liraglutide, and 101 to placebo and reported weight-loss and tolerability outcomes.

Phase 2 weight findings do not prove broad safety, long-term outcomes, or effectiveness of a 5 mg catalogue vial.

Human versus animal or cell evidence

Amylin-receptor biology supports satiety research but cannot establish clinical benefit by itself.

Limitations and known risks

Gastrointestinal adverse effects, long-term outcomes, combination effects, material identity, and final regulatory benefit-risk remain unresolved.

What this profile is—and is not

Concise source review published with formulation, jurisdiction, and evidence-strength limits; recheck before material revision.

This is sourced education, not medical advice or a personal-use recommendation. It does not validate the identity, purity, sterility, safety, or effectiveness of a catalogue material.